Immunization Against Genital Herpes with a Vaccine Virus That Has Defects in Productive and Latent Infection

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1999 Jun 9

PMID 10359827

Citations 56

Authors

X J Da Costa

C A Jones

D M Knipe

Affiliations

Soon will be listed here.

Abstract

An effective vaccine for genital herpes has been difficult to achieve because of the limited efficacy of subunit vaccines and the safety concerns about live viruses. As an alternative approach, mutant herpes simplex virus strains that are replication-defective can induce protective immunity. To increase the level of safety and to prove that replication was not needed for immunization, we constructed a mutant herpes simplex virus 2 strain containing two deletion mutations, each of which eliminated viral replication. The double-mutant virus induces protective immunity that can reduce acute viral shedding and latent infection in a mouse genital model, but importantly, the double-mutant virus shows a phenotypic defect in latent infection. This herpes vaccine strain, which is immunogenic but has defects in both productive and latent infection, provides a paradigm for the design of vaccines and vaccine vectors for other sexually transmitted diseases, such as AIDS.

Citing Articles

ICP8-vhs- HSV-2 Vaccine Expressing B7 Costimulation Molecules Optimizes Safety and Efficacy against HSV-2 Infection in Mice.

Korom M, Wang H, Bernier K, Geiss B, Morrison L Viruses. 2023; 15(7).

PMID: 37515256 PMC: 10384616. DOI: 10.3390/v15071570.

Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine.

Cheung F, Apps R, Dropulic L, Kotliarov Y, Chen J, Jordan T Elife. 2023; 12.

PMID: 36648132 PMC: 9844983. DOI: 10.7554/eLife.80652.

Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.

Zangi M, Donald K, Gazquez Casals A, Franson A, Yu A, Marker E Eur J Med Chem. 2022; 238:114443.

PMID: 35635945 PMC: 11103786. DOI: 10.1016/j.ejmech.2022.114443.

A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity.

Kaugars K, Dardick J, de Oliveira A, Weiss K, Lukose R, Kim J Proc Natl Acad Sci U S A. 2021; 118(34).

PMID: 34417304 PMC: 8403974. DOI: 10.1073/pnas.2110714118.

HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses.

Aschner C, Loh L, Galen B, Delwel I, Jangra R, Garforth S Sci Immunol. 2020; 5(50).

PMID: 32817296 PMC: 7673108. DOI: 10.1126/sciimmunol.aax2454.

References

Spang A, Godowski P, Knipe D . Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein. J Virol. 1983; 45(1):332-42. PMC: 256415. DOI: 10.1128/JVI.45.1.332-342.1983. View

Sawtell N, Thompson R . Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J Virol. 1992; 66(4):2157-69. PMC: 289008. DOI: 10.1128/JVI.66.4.2157-2169.1992. View

Sutter G, Moss B . Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A. 1992; 89(22):10847-51. PMC: 50439. DOI: 10.1073/pnas.89.22.10847. View

Sedarati F, Margolis T, Stevens J . Latent infection can be established with drastically restricted transcription and replication of the HSV-1 genome. Virology. 1993; 192(2):687-91. DOI: 10.1006/viro.1993.1089. View

Morrison L, Knipe D . Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol. 1994; 68(2):689-96. PMC: 236504. DOI: 10.1128/JVI.68.2.689-696.1994. View

Farrell H, McLean C, Harley C, Efstathiou S, Inglis S, Minson A . Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol. 1994; 68(2):927-32. PMC: 236530. DOI: 10.1128/JVI.68.2.927-932.1994. View

Bloom D, Stevens J . Neuron-specific restriction of a herpes simplex virus recombinant maps to the UL5 gene. J Virol. 1994; 68(6):3761-72. PMC: 236881. DOI: 10.1128/JVI.68.6.3761-3772.1994. View

Curtiss 3rd R, Kelly S, Tinge S, Tacket C, Levine M, Srinivasan J . Recombinant Salmonella vectors in vaccine development. Dev Biol Stand. 1994; 82:23-33. View

Sutter G, Wyatt L, Foley P, Bennink J, Moss B . A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 1994; 12(11):1032-40. DOI: 10.1016/0264-410x(94)90341-7. View

10.

Kramer M, Coen D . Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol. 1995; 69(3):1389-99. PMC: 188725. DOI: 10.1128/JVI.69.3.1389-1399.1995. View

11.

Speck P, Efstathiou S, Minson A . In vivo complementation studies of a glycoprotein H-deleted herpes simplex virus-based vector. J Gen Virol. 1996; 77 ( Pt 10):2563-8. DOI: 10.1099/0022-1317-77-10-2563. View

12.

Boursnell M, Entwisle C, Blakeley D, Roberts C, Duncan I, Chisholm S . A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis. 1997; 175(1):16-25. PMC: 7109964. DOI: 10.1093/infdis/175.1.16. View

13.

Da Costa X, Bourne N, Stanberry L, Knipe D . Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology. 1997; 232(1):1-12. DOI: 10.1006/viro.1997.8564. View

14.

Thompson R, Sawtell N . The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency. J Virol. 1997; 71(7):5432-40. PMC: 191783. DOI: 10.1128/JVI.71.7.5432-5440.1997. View

15.

Straus S, Wald A, Kost R, McKenzie R, Langenberg A, Hohman P . Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis. 1997; 176(5):1129-34. DOI: 10.1086/514103. View

16.

Dolan A, Jamieson F, Cunningham C, Barnett B, McGeoch D . The genome sequence of herpes simplex virus type 2. J Virol. 1998; 72(3):2010-21. PMC: 109494. DOI: 10.1128/JVI.72.3.2010-2021.1998. View

17.

Morrison L, Da Costa X, Knipe D . Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology. 1998; 243(1):178-87. DOI: 10.1006/viro.1998.9047. View

18.

Spector F, Kern E, Palmer J, Kaiwar R, Cha T, Brown P . Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis. 1998; 177(5):1143-54. DOI: 10.1086/515278. View

19.

Letvin N . Progress in the development of an HIV-1 vaccine. Science. 1998; 280(5371):1875-80. DOI: 10.1126/science.280.5371.1875. View

20.

Godowski P, Knipe D . Mutations in the major DNA-binding protein gene of herpes simplex virus type 1 result in increased levels of viral gene expression. J Virol. 1983; 47(3):478-86. PMC: 255289. DOI: 10.1128/JVI.47.3.478-486.1983. View